Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Pathology

Payment policy changes reduce ’25 cuts to pathologists

December 2024—Payment policies that the CAP championed to protect the value of pathology services have been captured in the 2025 Medicare physician fee schedule published on Nov. 1. The Centers for Medicare and Medicaid Services included in the 2025 fee schedule updated relative value units for three apheresis services and increased nonphysician cost components for key pathology and laboratory labor types. In a separate hospital payment regulation for 2025, the CMS also declined to move forward with surgical pathology tissue exam payment decreases to which the CAP objected.

Surveying cancer protocol use far and wide

November 2024—Members of the CAP Foundation Global Pathology Committee and the CAP Cancer Committee collaborated to develop a three-part webinar series on how to use the CAP cancer protocols. The webinars were directed to international pathologists, particularly those in low- and middle-income countries.

New Enhertu use, new HER2 complexities

September 2024—Every profession has its own news cycle. In pathology, the story arc is often a lengthy one, stretching from clinical triumph to Now what? Such is the case with expanded use of trastuzumab deruxtecan, which was granted accelerated FDA approval in late April for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received prior systemic treatment and have no alternative treatment options. Three multicenter trials evaluated the efficacy of the drug: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. PanTumor02 looked at seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other solid cancers (excluding breast, colorectal, gastric, and non-small cell lung cancers). The results of these trials often were striking (median duration of response for PanTumor02 was 19.4 months, for example), and physicians are now looking closely at this tumor-agnostic (also referred to as tissue-agnostic) indication.

Intraop neuropathology consultation: tips and cases

September 2024—Leomar Ballester, MD, PhD, of the University of Texas MD Anderson Cancer Center has simple advice for those called to provide an intraoperative neuropathologic consultation: review the imaging and know the entities.

Eyes on LDT inventory and cyberattack readiness

September 2024—The ADLM meeting in Chicago had just wrapped up when Compass Group members met online Aug. 6 with CAP TODAY publisher Bob McGonnagle. Stan Schofield, Compass Group VP and managing principal, noted Allina Health had announced in late June its definitive agreement with Quest Diagnostics for select assets of Allina’s laboratory services business, and Schofield reported plenty of M&A talk at the ADLM meeting. The group’s August discussion began there and moved to laboratory-developed tests and cybersecurity.

‘First of its kind’ update for cancer surveillance standards

September 2024—New cancer surveillance standards for tumor site, histology, and behavior code combinations and associated terms rolled out this year, after pathologists reviewed the combinations in an all-new effort. It’s an initiative known as Cancer PathCHART, short for Cancer Pathology Coding Histology and Registration Terminology, led by the National Cancer Institute with the support of 10 collaborating organizations, among them the CAP and the World Health Organization. “Nobody but the NCI could’ve done this. It’s been a great project,” says Kay Washington, MD, PhD, professor of pathology at Vanderbilt University Medical Center and a past member of the CAP Cancer Committee and American Joint Committee on Cancer.

AP lab panel on LDTs, digital path, workforce

August 2024—Digital pathology, FDA oversight of laboratory-developed tests, and the workforce shortage took center stage when CAP TODAY publisher Bob McGonnagle convened a roundtable online to talk about anatomic pathology laboratories. The shortage of pathologists, in particular, “is even greater than one might realize because of generational expectations around work-life balance,” said Andrew Bellizzi, MD, who applauds such balance but notes its significance. Their June 18 conversation follows.

Cytopathology in focus—Low-grade pancreatic neuroendocrine tumors in small samples: Grading challenges

August 2024—Two to five percent of pancreatic tumors are pancreatic neuroendocrine neoplasms, of which more than 90 percent are well-differentiated pancreatic neuroendocrine tumors (PanNETs). The current World Health Organization classification stratifies PanNETs into three histological grades based on mitotic count and Ki-67 proliferation index. Low-grade PanNETs (grades one and two) are morphologically indistinguishable and have characteristic neuroendocrine cytomorphologic features: a dispersed/loosely cohesive smear pattern composed of small-to-medium monomorphic cells with occasional plasmacytoid appearance; amphophilic, granular, or vacuolated cytoplasm; round nuclei; and coarse salt-and-pepper chromatin.

Digging into the interpretation of TSH results

Charna Albert May 2024—In a time of wellness testing and high rates of levothyroxine prescribing for hypothyroidism, it may also be time to rethink TSH test result interpretation. Laboratory testing is more accessible now than it used to be and patients are more involved in their own care. “You’re trying to give the patient access and ability to take care of their own health. But the double-edged sword is you can start over-ordering things, and the way we’ve designed lab

Labs juggle string of LDT unknowns

July 2024—Like a long-awaited second act, the FDA’s final rule regulating laboratory-developed tests as medical devices took the stage this spring. As with any FDA performance, this one opened to mixed reviews.

The spring curtain-raising followed the earlier proposed rule from last October, which drew some 6,500 responses during the public comment period. If that was an out-of-town tryout, no one quite knew what to expect from the rewrite, or if there would even be one.

As it turns out, there were indeed changes, but they didn’t necessarily bring clarity. As Jane Pine Wood, counsel for McDonald Hopkins, puts it, the final rule “certainly raised a whole lot more questions than it answered.”

The rule calls for a four-year, five-stage phaseout policy with the FDA enacting greater oversight of in vitro diagnostic products that are offered as LDTs.

Stage one, beginning on May 6, 2025, calls for labs to comply with medical device reporting requirements, correction and removal reporting requirements, and quality system requirements regarding complaint files.

MARKETPLACE

TRENDING